Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8445354 | 1.00 | CYP19A1 (1.00) | CYP19A1STS | |
| SCHEMBL8446302 | 0.93 | CYP19A1 (0.86) | CYP19A1STS | |
| SCHEMBL2702534 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL8446035 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL2700646 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL3233064 | 0.86 | CYP19A1 (1.00) | CYP19A1 | |
| SCHEMBL8445337 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL12189187 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL5035869 | 0.86 | CYP19A1 (0.76) | CYP19A1STS | |
| SCHEMBL8445536 | 0.86 | CYP19A1 (0.76) | CYP19A1STS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937251-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND AN AROMATASE INHIBITOR | Pfizer Products Inc. (US) | 2008-07-02 | — | — | EP | claimed |
| US-7345073-B2 | Method for treating cryptorchidism | HORMOS MEDICAL LTD. (FI) | 2008-03-18 | — | — | US | claimed |
| WO-2006114702-A2 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING A COMBINATION OF A SELECTIVE ESTROGEN RECEPTOR MODULATOR AND AN AROMATASE INHIBITOR | PFIZER PRODUCTS INC. (US) | 2006-11-02 | — | — | WO | claimed |
| EP-1653940-A1 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND AN AROMATASE INHIBITOR | Pharmacia Corporation (US) | 2006-05-10 | — | — | EP | claimed |
| EP-1303270-B1 | METHOD FOR TREATING CRYPTORCHIDISM | HORMOS MEDICAL LTD (FI) | 2006-03-29 | — | — | EP | claimed |
| US-20060030570-A1 | Method for treating cryptorchidism | HORMOS MEDICAL LTD. (FI) | 2006-02-09 | — | — | US | claimed |
| WO-2005027916-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS COMPRISING COMBINATIONS OF 2-ALKYLIDENE-19-NOR-VITAMIN D DERIVATIVES AND AROMATASE INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-03-31 | — | — | WO | claimed |
| US-20050065126-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and aromatase inhibitors | LEE ANDREW G (US) | 2005-03-24 | — | — | US | claimed |
| WO-2004093868-A1 | THERAPEUTIC COMBINATION OF A COX-2 INHIBITOR AND AN AROMATASE INHIBITOR | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | claimed |
| US-20040157808-A1 | Method for treating cryptorchidism | STRENG TOMI (FI) | 2004-08-12 | — | — | US | claimed |
| EP-1043993-B1 | USE OF AN AROMATASE INHIBITOR IN THE TREATMENT OF DECREASED ANDROGEN TO ESTROGEN RATIO AND DETRUSOR URETHRAL SPHINCTER DYSSYNERGIA IN MEN AND METHOD TO STUDY THE DYSSYNERGIA IN MALE RODENTS | HORMOS MEDICAL CORP (FI) | 2003-04-02 | — | — | EP | claimed |
| JP-2002508322-A | — | — | 2002-03-19 | — | — | JP | claimed |
| WO-2002009703-A1 | METHOD FOR TREATING CRYPTORCHIDISM | HORMOS MEDICAL CORPORATION (FI) | 2002-02-07 | — | — | WO | claimed |
| US-6316431-B1 | ENZYME INHIBITION BY ADMINISTERING AROMATIC NITRILES | HORMORS MEDICAL OY LTD. (FI) | 2001-11-13 | — | — | US | claimed |
| EP-1043993-A2 | USE OF AN AROMATASE INHIBITOR IN THE TREATMENT OF DECREASED ANDROGEN TO ESTROGEN RATIO AND DETRUSOR URETHRAL SPHINCTER DYSSYNERGIA IN MEN AND METHOD TO STUDY THE DYSSYNERGIA IN MALE RODENTS | Hormos Medical OY Ltd. (FI) | 2000-10-18 | — | — | EP | claimed |
| EP-0641785-B1 | TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMA CO LTD (JP) | 1999-10-27 | — | — | EP | claimed |
| US-5972921-A | UROGENITAL DISORDERS IN MALES | HORMOS MEDICAL OY LTD. (FI) | 1999-10-26 | — | — | US | claimed |
| WO-1999030708-A2 | USE OF AN AROMATASE INHIBITOR IN THE TREATMENT OF DECREASED ANDROGEN TO ESTROGEN RATIO AND DETRUSOR URETHRAL SPHINCTER DYSSYNERGIA IN MEN AND METHOD TO STUDY THE DYSSYNERGIA IN MALE RODENTS | HORMOS MEDICAL OY LTD. (FI) | 1999-06-24 | — | — | WO | claimed |
| US-5674886-A | AROMATASE INHIBITOR; BREAST CANCER; UROGENITAL DISORDERS | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 1997-10-07 | — | — | US | claimed |
| EP-0641785-A1 | TRIAZOLYLATED TERTIARY AMINE COMPOUND OR SALT THEREOF | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 1995-03-08 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157808-A1 | Method for treating cryptorchidism | CYP17A1, CYP21A2, CYP19A1 | CYP19A1 3/4885STS 127/4885 |
| US-20060030570-A1 | Method for treating cryptorchidism | CYP17A1, CYP21A2, CYP19A1 | CYP19A1 3/4885STS 127/4885 |
| US-20050065126-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and aromatase inhibitors | CYP19A1, CYP2R1, CYP24A1 | CYP19A1 1/4885STS 130/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.